Physician profile
Ming Fang
NPI 1366520199
$2,332.24
in general payments reported to CMS, 2019-2025
23 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $110 · 2021: $227 · 2022: $110 · 2023: $70.06 · 2024: $212 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.80 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.43 | 2019-2025 | |
| Janssen Biotech, INC. | $368.45 | 2019-2025 | Tremfya |
| Medtronic USA, INC. | $248.72 | 2019 | |
| Shionogi INC | $178.78 | 2019 | |
| Madrigal Pharmaceuticals | $158.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.03 | 2019-2024 | Xifaxan |
| Braintree Laboratories, INC. | $78.98 | 2024-2025 | Suflave, Sutab |
| Takeda Pharmaceuticals U.S.A., INC. | $72.36 | 2019 | |
| Pfizer INC. | $64.58 | 2019-2023 | |
| Genzyme Corporation | $47.17 | 2023 | |
| Gilead Sciences, INC. | $44.17 | 2025 | |
| Lilly USA, LLC | $41.17 | 2025 | Omvoh |
| Conmed Corporation | $39.58 | 2025 | Conmed Hemostasis, Conmed Dilation, Conmed Biopsy |
| Ferring Pharmaceuticals INC. | $21.60 | 2019 | |
| Intra-Sana Laboratories | $21.13 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.01 | 2024 | Voquezna |
| Mckesson Medical-Surgical, INC. | $17.61 | 2025 | |
| Capsovision, INC. | $17.23 | 2025 | Capsocam Plus |
| Merck Sharp & Dohme LLC | $17.03 | 2024 | |
| Celgene Corporation | $14.03 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $12.86 | 2020 | |
| Redhill Biopharma INC. | $12.59 | 2022 | |
| Qol Medical, LLC | $6.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Fang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.